ClinicalTrials.gg
RecruitingNCT07343869FEOUpdated Nov 6, 2026

Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection

An observational study in Superficial Esophageal Cancer, Oesophageal Adenocarcinoma and Oesophageal Squamous Cell Carcinoma, sponsored by Société Française d'Endoscopie Digestive. Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Société Française d'Endoscopie Digestive · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 6, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
750
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Adenocarcinoma Of Esophagus with a site in France — 12 open to participants now, 18 under way, 5 of them phase 3. Adenocarcinoma Of Esophagus · France.

Started
2026
with 4 others
Observational
4 of 36
1 open now
Primary completion
2031-12
later than 17 of 17 live
Registered
33rd of 36
by date

Among the 36 studies in Adenocarcinoma Of Esophagus with a site in France, this one is one of 5 that started in 2026, is one of 4 observational ones, reaches primary completion later than 17 of the 17 other live ones, and was the 33rd registered.

Adenocarcinoma Of Esophagus

354 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 80 are open to participants now.

Browse Adenocarcinoma Of Esophagus studies →

Open to participants now

12 of the 36 studies in Adenocarcinoma Of Esophagus with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Adenocarcinoma Of Esophagus with a site in France, or all of them as a file.
02

Study summary

In France in 2018, there were an estimated 2,074 new cases of esophageal adenocarcinoma and 3,224 cases of squamous cell carcinoma. The estimated deaths from esophageal cancer were 3,725, with a standardized 5-year net survival rate of 20% for cases diagnosed between 2010 and 2015, mainly due to late diagnosis.

Surgery was historically the standard treatment for localized disease but carries significant morbidity. Over the past decade, endoscopic treatments, particularly endoscopic submucosal dissection (ESD), have become the reference approach for superficial esophageal cancers.

After endoscopic resection, histological analysis allows classification of recurrence risk into very low, low, and high categories. Predicting lymph node or distant recurrence is complex, depending on factors such as depth of wall infiltration, lymphovascular invasion, and tumor differentiation. The frequent combination of unfavorable histological features may have led to an overestimation of lymph node involvement risk in T1b cancers.

ESD is widely performed in France, with over 1,600 procedures reported in 2023 for esophageal and gastric lesions, demonstrating the feasibility of a large observational study.

This multicenter French cohort will evaluate technical, oncological, and organizational outcomes of esophageal ESD, including overall survival, recurrence-free survival, and management of residual Barrett's esophagus. It will also identify predictive factors for treatment success, recurrence, and complications, providing real-world evidence to guide patient management.

03

Conditions studied

  • Superficial Esophageal Cancer
  • Oesophageal Adenocarcinoma
  • Oesophageal Squamous Cell Carcinoma
  • Barretts Esophagus With Dysplasia

Keywords

  • Endoscopic esophageal disection
  • Endoscopic resection
  • Endoscopic submucosal dissection
  • Curative resection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eligible patients include all individuals referred to a participating center for endoscopic resection of an esophageal lesion and treated by submucosal dissection. This is a prospective, multicenter, observational study, conducted on an intention-to-treat basis. All consecutive patients referred for esophageal ESD will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥ 18 years old)
  • Patients referred for endoscopic resection of an esophageal lesion and treated by submucosal dissection
  • Patients managed in one of the participating centers
  • Patient who has received oral and written information about the study and has not objected to participation
  • Patients covered by a social security or health insurance scheme.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal after reading the information sheet
  • Patient under legal protection (guardianship, curatorship, court-ordered protection)
  • Inability to inform the patient due to cognitive impairment, language barrier, or medical emergency
  • Patients previously included for another lesion in the same study
  • Pregnant or breastfeeding women.
  • Patient deprived of liberty.
  • Patient currently enrolled in another clinical trial.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
750 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Recurrence-free survival according to adjuvant treatment

    Recurrence-free survival will be evaluated in patients after endoscopic submucosal dissection (ESD) of superficial esophageal carcinoma. Patients may receive adjuvant therapy (surgery, chemotherapy, or chemoradiotherapy) at the treating physician's discretion. Recurrence includes local, regional, or metastatic relapse as defined by clinical, endoscopic, and imaging criteria and validated by multidisciplinary team discussion. Recurrence will be monitored throughout the 5-year follow-up period to compare outcomes between patients receiving adjuvant therapy versus surveillance.

    Time frame: From enrollment to 5 years

Secondary outcomes

  1. R0 resection rate

    Proportion of patients with tumor-free lateral and deep margins confirmed by histopathology.

    Time frame: From ESD to 5 years

  2. En bloc resection rate

    Proportion of lesions resected in a single piece exclusively by ESD.

    Time frame: From ESD to 5 years

  3. Curative resection rate

    Proportion of R0 resections meeting favorable histological criteria: no lymphovascular invasion, no tumor budding, well-differentiated tumor, submucosal invasion \<200 µm (squamous cell carcinoma) or \<500 µm (adenocarcinoma).

    Time frame: From ESD to 5 years

  4. 30-day complication rate

    Rate of per- or post-procedural bleeding, immediate or delayed perforation, and strictures requiring endoscopic dilation.

    Time frame: 30 days post-ESD

  5. Rate of MDTB presentation

    Proportion of patients whose management was discussed in a multidisciplinary team meeting.

    Time frame: From ESD to 5 years

  6. Concordance between MDTB decision and actual management

    Proportion of patients for whom the implemented management matched the MDTB recommendation.

    Time frame: From ESD to 5 years

  7. Rate of patients receiving adjuvant treatment

    Proportion of patients receiving any adjuvant therapy after ESD (surgery, radiotherapy, chemotherapy, immunotherapy, etc.).

    Time frame: From enrollment to 5 years

  8. Rate of complementary Barrett's eradication treatment (radiofrequency or other)

    Proportion of patients treated for residual Barrett's esophagus using radiofrequency ablation or other endoscopic techniques.

    Time frame: From ESD to 5 years

  9. Morbidity of complementary treatments

    Rate of complications related to adjuvant therapy or Barrett's treatment

    Time frame: From ESD to 5 years

  10. Efficacy of complementary treatments

    Rate of complete remission of intestinal metaplasia or oncologic control following complementary tratmets

    Time frame: From complementary treatment to 5 years

  11. Prognostic factors for recurrence (local, regional, metastatic)

    Identification of clinical, endoscopic, and histological variables associated with increased risk of recurrence, analyzed using univariate and multivariate methods.

    Time frame: From enrollment to 5 years

  12. Predictive factors for post-ESD complications

    Analysis of factors associated with immediate or delayed complications (bleeding, perforation, stenosis) according to patient characteristics, ESD procedure, and adjuvant therapy.

    Time frame: From ESD to 5 years

  13. Predictive factors for R0 resection

    Analysis of clinical, endoscopic, and procedural variables predictive of complete R0 resection.

    Time frame: From ESD to 5 years

  14. Diagnostic accuracy of optical endoscopic classifications vs. histology

    Accuracy of endoscopic optical classifications in predicting histology prior to resection, compared to histopathology results.

    Time frame: From ESD to pathology report

  15. Impact of center volume on outcomes

    Evaluation of the influence of annual ESD procedure volume in a center on technical and oncologic outcomes

    Time frame: From enrollment to 5 years

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Dec 2031, 68 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Mar 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Jan 15, 2026
StartActual
Mar 11, 2026was Feb 2026
Primary completionEst.
Dec 1, 2031
CompletionEst.
Feb 1, 2036
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
6 sites added. Jules Verne Clinic is now Recruiting
Show 6 added (6 France)
  • CHU de Bordeaux - Hôpital Haut-Lévêque · Bordeaux, France
  • CHU de Limoges - Hôpital Dupuytren 1 · Limoges, France
  • Hôpital Édouard Herriot · Lyon, France
  • CHRU de Nancy - Hôpital Brabois · Nancy, France
  • CHU de Rennes - Hôpital Pontchaillou · Rennes, France
  • Clinique Saint-Hilaire · Rouen, France
Nov 6, 2026
Start date
Feb 1, 2026→Mar 11, 2026 (actual)
Nov 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Jules Verne Clinic · Nantes, FranceContact added b•••@gmail.com · •••6383
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    6 sites added. Jules Verne Clinic is now Recruiting
    Show 6 added (6 France)
    • CHU de Bordeaux - Hôpital Haut-Lévêque · Bordeaux, France
    • CHU de Limoges - Hôpital Dupuytren 1 · Limoges, France
    • Hôpital Édouard Herriot · Lyon, France
    • CHRU de Nancy - Hôpital Brabois · Nancy, France
    • CHU de Rennes - Hôpital Pontchaillou · Rennes, France
    • Clinique Saint-Hilaire · Rouen, France
    Start date Feb 1, 2026→Mar 11, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Jules Verne Clinic · Nantes, FranceContact added b•••@gmail.com · •••6383
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07343869
Lead sponsor
Société Française d'Endoscopie Digestive
Responsible party
Bertrand Brieau (Principal Investigator, Medical doctor, Société Française d'Endoscopie Digestive) — Principal investigator
First posted
Jan 15, 2026
Start date
Mar 11, 2026
Primary completion
Dec 1, 2031 (estimated)
Completion
Feb 1, 2036 (estimated)
Last update
Nov 6, 2026

Study contacts

Bertrand BB BRIEAU, MD
Contact
bertrand.brieau@gmail.com
+33650266383 ext. +33
Maira MORENO, PhD
Contact
rechercheclinique@sfed.org
+33(0)472117513

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion